Urologic Diseases  >>  Rencarex (girentuximab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
NCT00606632: Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

Completed
3
226
US
124-Iodine-cG250 (124I-cG250), Ca9-SCAN, CT
Heidelberg Pharma AG
Renal Cell Carcinoma, Kidney Cancer
11/09
12/09
NCT00087022 / 2004-000353-38: Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Completed
3
864
Canada, US, RoW
girentuximab, Rencarex®, cG250 and WX-G250, placebo
Heidelberg Pharma AG
Kidney Cancer
10/12
10/12
REDECT 2, NCT01762592: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Withdrawn
3
0
US
Iodine (124I) Girentuximab, 124I-cG250
Heidelberg Pharma AG
Renal Cell Carcinoma, Kidney Cancer
12/18
12/19

Download Options